ArticleCancer immunology, immunotherapy : CII2020

CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1.

Nuray Erin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.